Marbofloxacin

Animal-derived bacterial resistance has become a key prevention and control issue in the global public health field, so new antibacterial veterinary API with high efficiency and low residue have attracted great attention from the industry. Marbofloxacin is a fluoroquinolone antibacterial drug exclusively for animals. It exerts a bactericidal effect by inhibiting the activity of bacterial DNA gyrase and topoisomerase IV and blocking the bacterial DNA replication process. It has strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and some mycoplasmas. Clinically, it is mainly used to treat respiratory tract infections, digestive tract infections, urinary tract infections and skin and soft tissue infections in dogs and cats, and can also be used for the prevention and control of bacterial diseases in livestock and poultry such as pigs and cattle. It is one of the core drugs for anti-infective treatment of livestock, poultry and companion animals at present.

The global marbofloxacin market size was approximately USD 180 million in 2023, with a compound annual growth rate of 6.2% in the past five years. The growth momentum mainly comes from the rapid expansion of companion animal diagnosis and treatment demand and the trend of upgrading and replacement of antibacterial drugs in the livestock and poultry breeding sector. At present, the competitive pattern of the domestic market is dominated by generic drug enterprises, and European original research manufacturers account for about 40% of the high-end pet medical market. Local API manufacturers have achieved export by virtue of cost advantages, and the export volume of domestic marbofloxacin API accounted for 62% of the total output in 2023. With the continuous improvement of the penetration rate of the domestic pet medical market, it is expected that the growth rate of domestic market demand will remain above 8% in the next three years.

The original research enterprise of marbofloxacin is Virbac France, with the original research trade name "Marbocyl". Its core compound patent in the European Union expired in 2011, and the Chinese compound patent also expired in 2011. The main dosage forms of the original research product include injection and tablets, with common specifications of 20 mg/tablet, 80 mg/tablet and 10 mg/ml injection. Both the tablets and the injection have been included in the China Listed Drug Catalogue as reference preparations, and are also included in the FDA Reference Preparation Catalogue. As of the retrieval time point, 12 domestic enterprises have obtained A status for their marbofloxacin API through CDE registration, and more than 30 other enterprises have obtained approval for the marketing of their marbofloxacin preparation products. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of marbofloxacin impurity reference standards, covering the needs of the entire research chain including synthesis process impurities and degradation impurities. Most products are in stock, and orders placed before 16:00 can be shipped on the same day. All reference standards meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and fully meet the needs of various scenarios of API enterprises such as registration and declaration, quality research and routine release testing.